NCT04725110View on ClinicalTrials.gov

Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

January 15, 2026

Primary Completion Date

October 15, 2030

Study Completion Date

October 15, 2031

Conditions
Covid19SARS-CoV InfectionARDSARDS, Human
Interventions
DRUG

Instilled T3

The first dose of T3 (50 micrograms in 10 mls volume BID) will be instilled by an investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. T3 doses will be given in 50 mcg doses twice daily for 4 days.

OTHER

Placebo Therapy

A placebo therapy will be instilled into the lungs by the investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. Doses will be given twice daily for 4 days.

Trial Locations (1)

55117

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER